Rhodium(III)-Catalyzed Regioselective Direct C4-Alkylation and C2-Annulation of Indoles: Straightforward Access to Indolopyridone
作者:Aniruddha Biswas、Rajarshi Samanta
DOI:10.1002/ejoc.201701755
日期:2018.3.29
C4‐alkylation and C2‐annulation of indole derivative has been developed by using variable diazo esters. Fine tuning of the reactivity of diazo esters leads to control in regioselectivity with wide scope and functional‐group tolerance. A straightforward approach has been established to furnish an indolopyridone scaffold.
[EN] INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)<br/>[FR] COMPOSÉS INDOLIQUES OU ANALOGUES DE CEUX-CI UTILES DANS LE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE (DMLA)
申请人:NOVARTIS AG
公开号:WO2012093101A1
公开(公告)日:2012-07-12
The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Method of inhibiting neoplastic cells with indole derivatives
申请人:Cell Pathways, Inc.
公开号:US06358992B1
公开(公告)日:2002-03-19
A method for inhibiting neoplasia, particularly cancerous and precancerous lesions, by exposing the affected cells to indole derivatives.
一种通过将受影响的细胞暴露于吲哚衍生物来抑制肿瘤,特别是癌性和癌前病变的方法。
Indole derivatives as cGMP-PDE inhibitors
申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US06069156A1
公开(公告)日:2000-05-30
Compounds of the formula (I): ##STR1## and their pharmaceutically acceptable compositions are useful in inhibiting the activity of cyclic guanosine 3',5'-monophosphate phosphodiesterase.
[EN] AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS AMINO POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
申请人:ACHILLION PHARMACEUTICALS INC
公开号:WO2017035351A1
公开(公告)日:2017-03-02
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.